
Shares of medtech firm Lensar LNSR.O rise 28.8% to $12.20 in afternoon trade
Company posts Q4 revenue of $16.7 million, benefiting from its cataract surgery tech system, ALLY, beating analysts' estimates of $14.90 million, according to data compiled by LSEG
Company posts Q4 net loss of $1.61 per share, vs estimates of 18 cents
Expects Q1 revenue growth to align with 2024 rate
In the past 12 months, LNSR up 94%